DSGN Earnings Date: Nov 4, 2026 (Estimated) — Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is DSGN's next earnings date?
Design Therapeutics, Inc. (DSGN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.38.
How did DSGN do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), Design Therapeutics, Inc. posted EPS of -$0.32 versus the -$0.35 estimate, a beat of 8.6%. Revenue was $0. The stock's 1-day post-earnings move was +4.8%.
How much does DSGN stock move after earnings?
DSGN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | -0.35 | -0.32 | +8.57% | $0 | ✅ Beat | +4.76% | +14.86% | +23.89% |
| 2026-04-28 | Q1 2026 | -0.34 | -0.29 | +14.71% | $0 | ✅ Beat | +23.26% | +4.68% | -16.16% |
| 2026-03-09 | Q4 2025 | -0.36 | -0.27 | +25.00% | $0 | ✅ Beat | -3.66% | +5.98% | +22.18% |
| 2025-11-05 | Q3 2025 | -0.34 | -0.30 | +11.76% | $0 | ✅ Beat | +4.89% | +16.18% | +49.16% |
| 2025-08-07 | Q2 2025 | -0.33 | -0.34 | -3.03% | $0 | ❌ Miss | -8.74% | +24.60% | +48.28% |
| 2025-03-10 | Q4 2024 | -0.27 | -0.24 | +11.11% | $0 | ✅ Beat | -1.02% | -4.37% | -36.18% |
| 2024-11-07 | Q3 2024 | -0.24 | -0.23 | +4.17% | $0 | ✅ Beat | +0.69% | +3.97% | +12.44% |
| 2024-05-08 | Q1 2024 | -0.29 | -0.20 | +31.03% | $0 | ✅ Beat | +1.71% | -3.84% | -17.91% |
Showing last 8 quarters.